Provided by Tiger Fintech (Singapore) Pte. Ltd.

CINGULATE INC.

4.20
-0.2000-4.55%
Post-market: 4.19-0.0100-0.24%19:38 EDT
Volume:66.89K
Turnover:281.94K
Market Cap:17.83M
PE:-0.41
High:4.46
Open:4.30
Low:4.12
Close:4.40
Loading ...

Cingulate Inc Approves Key Proposals at Annual Meeting

TIPRANKS
·
11 Jun

Cingulate Inc. Conducted Annual Stockholders Meeting

Reuters
·
11 Jun

Cingulate Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
27 May

Roth MKM Sticks to Their Buy Rating for Cingulate Inc (CING)

TIPRANKS
·
23 May

Cingulate announces efficacy results from Phase 3 study of CTx-1301

TIPRANKS
·
20 May

Efficacy Results Announced From Cingulate’s Phase 3 Pediatric Study of Ctx-1301 (Dexmethylphenidate) for Adhd

THOMSON REUTERS
·
20 May

Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD

GlobeNewswire
·
20 May

Cingulate Is Maintained at Buy by Roth Capital

Dow Jones
·
20 May

Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), Waters (WAT) and Cingulate Inc (CING)

TIPRANKS
·
19 May

Cingulate price target lowered to $11 from $12 at Roth Capital

TIPRANKS
·
19 May

FDA and Cingulate Aligned With Filing Requirements for New Drug Application for Lead Adhd Asset Ctx-1301

THOMSON REUTERS
·
14 May

Cingulate Inc - Plans Nda Submission for Ctx-1301 This Summer

THOMSON REUTERS
·
14 May

Cingulate Inc: Pre-Nda Meeting With FDA Is Aligned With Plans to Submit a Nda for Ctx-1301 This Summer

THOMSON REUTERS
·
14 May

Cingulate Inc Terminates Grant Agreement with Foundation

TIPRANKS
·
14 May

Cingulate Q1 EPS $(1.04) Misses $(0.92) Estimate

Benzinga
·
09 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 May

Cingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301

TIPRANKS
·
30 Apr

BRIEF-Cingulate Announces Positive Top-Line Results From High-Dose (50Mg) Fed/Fast Study Of Lead Asset Ctx-1301 For Adhd

Reuters
·
29 Apr

Cingulate Announces Positive Top-Line Results From High-Dose (50Mg) Fed/Fast Study of Lead Asset Ctx-1301 for Adhd

THOMSON REUTERS
·
29 Apr

Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD

GlobeNewswire
·
29 Apr